Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05760248 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
A Phase 2 study, sponsored by 10xBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT05760248: Completed Phase 2 study, sponsored by 10xBio.
NCT05760248 is a Phase 2 study that has completed, run by 10xBio. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05760248, a Phase 2 study, has completed, sponsored by 10xBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Participants will be: * Be given injections every month for 5 months over the right and left flanks. * Be asked to be seen in the clinic for 13 visits and 3 phone call visits during a duration of 1 year.
Interventions
- DRUG 10XB-101 Solution for Injection, 6.0%
- DRUG Placebo Solution for Injection (no active ingredient)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05760248
The ClinicalTrials.gov registry entry for NCT05760248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). The listed sponsor is 10xBio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 10XB-101 Solution for Injection, 6.0% is the first listed.
NCT05760248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05760248 about?
NCT05760248 is a clinical study titled "Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity". The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Part...
What is the current status of trial NCT05760248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2023-05-04. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT05760248?
The interventions under investigation include: 10XB-101 Solution for Injection, 6.0% (DRUG), Placebo Solution for Injection (no active ingredient) (DRUG).
Who is sponsoring clinical trial NCT05760248?
This trial is sponsored by 10xBio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.